Single-Hormone Artificial Pancreas Use in Diabetes: Clinical Efficacy and Remaining Challenges | Zendy

Nadine Taleb | Zendy; Sémah Tagougui | Zendy; Rémi RabasaLhoret | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Single-Hormone Artificial Pancreas Use in Diabetes: Clinical Efficacy and Remaining Challenges

Author(s) -

Nadine Taleb,

Sémah Tagougui,

Rémi RabasaLhoret

Publication year - 2019

Publication title -

diabetes spectrum

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.716

H-Index - 31

eISSN - 1944-7353

pISSN - 1040-9165

DOI - 10.2337/ds18-0094

Subject(s) - medicine , hypoglycemia , artificial pancreas , diabetes mellitus , insulin , concomitant , hormone , psychological intervention , intensive care medicine , clinical trial , diabetes management , pancreas , bioinformatics , endocrinology , type 2 diabetes , type 1 diabetes , psychiatry , biology

IN BRIEF Artificial pancreas systems are rapidly developing and constitute the most promising technology for insulin-requiring diabetes management. Single-hormone systems (SH-AP) that deliver only insulin and have a hybrid design that necessitates patients’ interventions around meals and exercise are the first to appear on the market. Trials with SH-AP have demonstrated improvement in time spent with blood glucose levels within target ranges, with a concomitant decrease in hypoglycemia. Longer and larger trials involving different patient populations are ongoing to further advance this important technology.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research